Chapman M John相关文献与解析，生知库 | 链接生命科学的每一步

Acute myocardial infarction preferentially alters low-abundant, long-chain unsaturated phospholipid and sphingolipid species in plasma high-density lipoprotein subpopulations

急性心肌梗死优先改变血浆高密度脂蛋白亚群中低丰度的长链不饱和磷脂和鞘脂种类。

doi:10.1016/j.athplu.2023.12.001

Ponnaiah, Maharajah; Zakiev, Emile; Lhomme, Marie; Rached, Fabiana; Camont, Laurent; Serrano, Carlos V Jr; Santos, Raul D; Chapman, M John; Orekhov, Alexander; Kontush, Anatol

HDL functionality in type 1 and type 2 diabetes: new insights

高密度脂蛋白在1型和2型糖尿病中的功能：新见解

期刊:Current Opinion in Endocrinology Diabetes and Obesity

影响因子:2.7

doi:10.1097/MED.0000000000000705

Differentiating EPA from EPA/DHA in cardiovascular risk reduction

区分EPA和EPA/DHA在降低心血管风险方面的作用

期刊:American Heart Journal Plus

影响因子:1.8

doi:10.1016/j.ahjo.2022.100148

Toth, Peter P; Chapman, M John; Parhofer, Klaus G; Nelson, John R

发表日期：2022

文献求助收藏

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society

富含甘油三酯的脂蛋白及其残余物：代谢见解、在动脉粥样硬化性心血管疾病中的作用以及新兴治疗策略——欧洲动脉粥样硬化协会共识声明

期刊:European Heart Journal

影响因子:35.6

doi:10.1093/eurheartj/ehab551

Ginsberg, Henry N; Packard, Chris J; Chapman, M John; Borén, Jan; Aguilar-Salinas, Carlos A; Averna, Maurizio; Ference, Brian A; Gaudet, Daniel; Hegele, Robert A; Kersten, Sander; Lewis, Gary F; Lichtenstein, Alice H; Moulin, Philippe; Nordestgaard, Børge G; Remaley, Alan T; Staels, Bart; Stroes, Erik S G; Taskinen, Marja-Riitta; Tokgözoğlu, Lale S; Tybjaerg-Hansen, Anne; Stock, Jane K; Catapano, Alberico L

Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges

强化降低低密度脂蛋白胆固醇在心血管疾病预防中的应用：机遇与挑战

期刊:Heart

影响因子:4.4

doi:10.1136/heartjnl-2020-318760

Packard, Chris; Chapman, M John; Sibartie, Mahendra; Laufs, Ulrich; Masana, Luis

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

低密度脂蛋白导致动脉粥样硬化性心血管疾病：病理生理学、遗传学和治疗学见解：欧洲动脉粥样硬化学会共识小组的共识声明

期刊:European Heart Journal

影响因子:35.6

doi:10.1093/eurheartj/ehz962

Borén, Jan; Chapman, M John; Krauss, Ronald M; Packard, Chris J; Bentzon, Jacob F; Binder, Christoph J; Daemen, Mat J; Demer, Linda L; Hegele, Robert A; Nicholls, Stephen J; Nordestgaard, Børge G; Watts, Gerald F; Bruckert, Eric; Fazio, Sergio; Ference, Brian A; Graham, Ian; Horton, Jay D; Landmesser, Ulf; Laufs, Ulrich; Masana, Luis; Pasterkamp, Gerard; Raal, Frederick J; Ray, Kausik K; Schunkert, Heribert; Taskinen, Marja-Riitta; van de Sluis, Bart; Wiklund, Olov; Tokgozoglu, Lale; Catapano, Alberico L; Ginsberg, Henry N

Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics

REDUCE-IT试验中，二十碳五烯酸乙酯显著降低了首次和总心血管事件的发生率：这些结果为何开启了血脂异常治疗的新时代？

期刊:European Heart Journal

影响因子:35.6

doi:10.1093/eurheartj/ehz778

Boden, William E; Bhatt, Deepak L; Toth, Peter P; Ray, Kausik K; Chapman, M John; Lüscher, Thomas F

Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap

二十碳五烯酸乙酯治疗高甘油三酯血症的疗效和安全性：综述

期刊:European Heart Journal Supplements

影响因子:2.5

doi:10.1093/eurheartj/suaa116

Parhofer, Klaus G; Chapman, M John; Nordestgaard, Børge G

发表日期：2020

文献求助收藏

Beyond cardiovascular medicine: potential future uses of icosapent ethyl

心血管医学之外：二十碳五烯酸乙酯的潜在未来用途

期刊:European Heart Journal Supplements

影响因子:2.5

doi:10.1093/eurheartj/suaa119

Bhatt, Deepak L; Hull, Mark A; Song, Mingyang; Van Hulle, Carol; Carlsson, Cindy; Chapman, M John; Toth, Peter P

发表日期：2020

文献求助收藏

Lipoprotein(a) Is Markedly More Atherogenic Than LDL: An Apolipoprotein B-Based Genetic Analysis

脂蛋白(a)比低密度脂蛋白(LDL)更具致动脉粥样硬化作用：基于载脂蛋白B的基因分析

Acute myocardial infarction preferentially alters low-abundant, long-chain unsaturated phospholipid and sphingolipid species in plasma high-density lipoprotein subpopulations

急性心肌梗死优先改变血浆高密度脂蛋白亚群中低丰度的长链不饱和磷脂和鞘脂种类。

HDL functionality in type 1 and type 2 diabetes: new insights

高密度脂蛋白在1型和2型糖尿病中的功能：新见解

Differentiating EPA from EPA/DHA in cardiovascular risk reduction

区分EPA和EPA/DHA在降低心血管风险方面的作用

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society

富含甘油三酯的脂蛋白及其残余物：代谢见解、在动脉粥样硬化性心血管疾病中的作用以及新兴治疗策略——欧洲动脉粥样硬化协会共识声明

Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges

强化降低低密度脂蛋白胆固醇在心血管疾病预防中的应用：机遇与挑战

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

低密度脂蛋白导致动脉粥样硬化性心血管疾病：病理生理学、遗传学和治疗学见解：欧洲动脉粥样硬化学会共识小组的共识声明

Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics

REDUCE-IT试验中，二十碳五烯酸乙酯显著降低了首次和总心血管事件的发生率：这些结果为何开启了血脂异常治疗的新时代？

Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap

二十碳五烯酸乙酯治疗高甘油三酯血症的疗效和安全性：综述

Beyond cardiovascular medicine: potential future uses of icosapent ethyl

心血管医学之外：二十碳五烯酸乙酯的潜在未来用途